2112, 2017

CIS Pharma has reached the first milestone in its SNI funded project

Bubendorf, Switzerland, Thursday, December 21, 2017 - CIS Pharma’s bio-membrane project has reached the first milestone. The polymer chemistry experts developed the a first prototype compatible with the 3D printing process. As key project milestones are achieved, the Swiss Nanoscience Institute will grant CIS Pharma a prolonged funding of its bio-membrane project: the cooperation with the University of Applied Sciences, [...]

812, 2017

CIS Pharma Christmas event at Palazzo Colombino

Basel, Switzerland, Friday, December 8, 2017 - We spend the night at Palazzo Colombino, a Variété that offers a night with delishes food and spectacular artistic performances. The exquisite dishes are created by the renowned chef of "Les Quatres Saisons", Peter Moser, each a feast for the eyes and culinary delight. What a spectacular evening, being taken into a world [...]

2410, 2017

CIS Pharma team attends CPhI Worlwide 2017 in Frankfurt

Frankfurt, Germany, Tuesday to Thursday, October 24 to 26, 2017 – CIS Pharma is attending CPhI Worlwide to meet development partners and licensees during the three-day conference in Frankfurt. The team is setting out to meet face-to-face project partners and to source solutions for their innovation projects. As a number of meetings are scheduled we are kindly asking to confirm [...]

1610, 2017

CIS Pharma verified compatibility of its polymer-drug carriers to be used in antibody-drug conjugates and antibody-radionuclid conjugates

Bubendorf, Switzerland, Monday, October 16, 2017 - The polymer experts from CIS Pharma successfully accomplished a first proof-of-concept study on the compatibility of their polymer-drug carriers with a conjugation technique of NBE Therapeutics. The polymer-drug carrier loaded with tracer molecules was enzymatically conjugated to a model antibody and the ADC subsequently analyzed for its affinity to bind the target. In [...]

109, 2017

Mylotarg, a new antibody-drug conjugate, ADC, approved by the FDA for treatment of acute myeloid leukemia

Maryland, USA, Friday, September 1, 2017 - The U.S. Food and Drug Administration approved the ADC Mylotarg, gemtuzumab ozogamicin, for the treatment of adults with newly diagnosed acute myeloid leukemia, whose tumors express the CD33 antigen. The FDA also approved Mylotarg for the treatment of patients aged 2 years and older with CD33 who have experienced a relapse or who [...]

2007, 2017

CIS Pharma summer event in Alsace

Strasbourg, France, Thursday, July 20, 2017 - The CIS Pharma Summer Event takes us to Alsace, France. Our first stop is well known in France and abroad for its foie gras, the farm of Lucien Doriath in Soulz-les-Bains. At the in-house restaurant, we indulge in delicacies. Our next stop is at the Domaine Agapé in Riquewihr on the Alsace Route [...]

2906, 2017

Besponsa, a new antibody-drug conjugate, ADC, approved in the EU

London, GB, Thursday, June 29, 2017 - The ADC Besponsa - inotuzumab ozogamicin, Pfizer Inc. - is a cancer medicine used to treat a type of blood cancer which affects B cells called “B-cell precursor acute lymphoblastic leukaemia”. Besponsa is used on its own in adults whose cancer has come back or did not respond to previous treatment. It is [...]

405, 2017

CIS Pharma presenting ADC drug carrier technology at Swiss Biotech Day 2017

Basel, Switzerland, Thursday, May 4, 2017 - CIS Pharma presents its ADC drug carrier technology at Swiss Biotech Day 2017, scheduled for 14:10 during the Emerging Companies Streams. CIS Pharma ADC drug carriers are based on the proprietary Cellophil® Smart Polymer technology that allows the ADCs to be custom designed for delivery of a wide array of anti-tumor agents directly [...]

2604, 2017

CIS Pharma starts R&D project by SNI for 3D printed biocompatible membranes for tissue regeneration

Bubendorf, Switzerland, Wednesday, April 26, 2017 - The Swiss Nanoscience Institute has granted CIS Pharma funding for an innovative project in the field of implantology. The Project is a collaboration between the University of Applied Science, FHNW in Muttenz and the High-tech Research Center in Basel. During this project a biocompatible membrane is developed to enhance tissue regeneration at the [...]

102, 2017

CIS Pharma team attends Pharmapack 2017 in Paris

Paris, France, Wednesday to Thursday, February 1 to 2, 2017 – CIS Pharma is attending CPhI Worlwide to meet development partners and licensees during the two-day conference in Paris. The team is setting out to meet face-to-face project partners and to source solutions for their innovation projects. As a number of meetings are scheduled we are kindly asking to confirm [...]

112, 2016

CIS Pharma appoints Dr. Christophe Thommen as new head of research and laboratory operations

Bubendorf, Switzerland, Thursday, December 1, 2016 - CIS Pharma welcomes Dr. Christophe Thommen, who will lead the research team as the new head of research and laboratory operations. Christophe is an expert in natural products chemistry and his expertise has already led to a number of innovative and efficient syntheses in the industry. With his focus on scalability and industrialization [...]

2110, 2016

CIS Pharma’s solubilization technology comprising cyclosporine A has entered proof of concept phase

Bubendorf, Switzerland, Friday, October 21, 2016 - CIS Pharma’s novel solubilization strategy for hydrophobic drugs has successfully reached the proof of concept phase. The Cellophil® Smart Polymer technology platform creates water-soluble formulations for a number of model drugs such as cyclosporine A. The technology can be applied to a large number of water-insoluble drugs, improving the bioavailability and tolerance for [...]

410, 2016

CIS Pharma team attends CPhI Worlwide 2016 in Barcelona

Barcelona, Spain, Tuesday to Thursday, October 4 to 6, 2016 – CIS Pharma is attending CPhI Worlwide to meet development partners and licensees during the three-day conference in Barcelona. The team is setting out to meet face-to-face project partners and to source solutions for their innovation projects. As a number of meetings are scheduled we are kindly asking to confirm [...]

509, 2016

CIS Pharma has successfully concluded the development of novel contact lens coating technology

Bubendorf, Switzerland, Monday, September 5, 2016 - CIS Pharma has concluded the development of a novel contact lens coating technology based on the Cellophil® Smart Polymer platform. The technology has been shown to increase surface wettability and lubricity and is expected to increase the wear comfort of silicone hydrogel contact lenses. CIS Pharma has created novel bio-inspired polymer derivatives based [...]

108, 2016

CIS Pharma to launch new web presence

Bubendorf, Switzerland, Monday, August 1, 2016 - CIS Pharma’s new company website is online. The site was established in collaboration with SKYWEB, a fast-growing start-up incorporated in close proximity to CIS Pharma. The new web presence supports the mobile lifestyle of customers and offers an overview of our projects. For questions relating to our technology portfolio, please feel free to [...]

1606, 2016

CIS Pharma has developed contact lens care products based on its new patented technology platform

Bubendorf, Switzerland, Friday, June 16, 2016 - CIS Pharma has developed a novel multipurpose solution for contact lenses. With over 25 years of experience and a track record of several lens care products licensed to and sold by partners globally, the team has developed the next generation contact lens care solution that increases contact lens wear comfort while keeping the [...]

2405, 2016

Approval received for intracameral cefuroxime for antibiotic prophylaxis of endophthalmitis after cataract surgery

Uppsala, Sweden, Mai 24, 2016 – The marketing authorization application for intracameral cefuroxime has been finalized with a positive outcome. The decentralized procedure was led by Sweden as reference member states with a total of seventeen reference member states across Europe. As a result, a large number of cataract clinics in Europe will benefit from the intracameral injection of cefuroxime [...]

1004, 2016

Development of vial adaptor for preparation of intracameral cefuroxime

Bubendorf, April 10, 2016 – CIS Pharma enters agreement with West Pharma to develop a vial adaptor specific for the preparation and injection of intracameral cefuroxime. The development is innovative device that prevents the 10mg/ml cefuroxime sodium solution from particulate contamination, containing several 5-micron filters. After reconstitution of the cefuroxime powder, the vial adaptor separates into two parts, immediately offering [...]

1002, 2016

CIS Pharma team attends Pharmapack 2016 in Paris

Paris, France, Wednesday to Thursday, February 10 to 11, 2016 – CIS Pharma is attending CPhI Worlwide to meet development partners and licensees during the two-day conference in Paris. The team is setting out to meet face-to-face project partners and to source solutions for their innovation projects. As a number of meetings are scheduled we are kindly asking to confirm [...]

2101, 2016

CIS Pharma announces the first milestones in its ADC research program are achieved

Bubendorf, Switzerland, Thursday, January 21, 2016 - Proof of concept studies at NBE Therapeutics demonstrated conjugation of CIS Pharma’s Cellophil® Smart Polymer drug carrier to antibodies. Consequently, different linkers were evaluated for loading the drug carrier with anti-cancer moieties. CIS Pharma has successfully loaded its proprietary Cellophil® Smart Polymer drug carriers with model compounds for cancer therapies. CIS Pharma [...]

1711, 2015

CIS Pharma creates novel contact lens coating technology

Bubendorf, Switzerland, Tuesday, November 17, 2015 - CIS Pharma is expanding its Cellophil® Smart Polymer platform with new bio-inspired derivatives. The derivatives are used as building blocks for the development of a novel contact lens coating technology. The Cellophil® Smart Polymer coating technology aims to improve the wettability of silicone hydrogel contact lenses. In addition, the coating is designed to [...]

1310, 2015

CIS Pharma team attends CPhI Worlwide 2015 in Madrid

Madrid, Spain, Tuesday to Thursday, October 13 to 15, 2015 – CIS Pharma is attending CPhI Worlwide to meet development partners and licensees during the three-day conference in Madrid. The team is setting out to meet face-to-face project partners and to source solutions for their innovation projects. As a number of meetings are scheduled we are kindly asking to confirm [...]

209, 2015

CIS Pharma develops solubilization technology for hydrophobic drugs

Bubendorf, Switzerland, Tuesday, September 2, 2015 - CIS Pharma has engaged in a research program to develop a new technology platform that creates water-soluble formulations of highly hydrophobic drugs. The approach comprises a polymer-based solubilization technology that can be applied to a large number of water-insoluble drugs. The technology aims to improve the bioavailability and tolerance for drugs used in [...]

2007, 2015

Submission of marketing authorization application for intracameral cefuroxime completed

Uppsala, Sweden, July 20, 2015 – CIS Pharma has submitted to the Swedish competent authority MPA the marketing authorization application for intracameral cefuroxime. The decentralized procedure is led by Sweden as reference member states with a total of seventeen reference member states across Europe. The CIS Pharma team is proud to have achieved the first major milestone in the agreement [...]

1206, 2015

CIS Pharma creates next generation contact lens care products

Bubendorf, Switzerland, Friday, June 12, 2015 - CIS Pharma is investigating novel formulations and combinations of active ingredients to improve contact lens care. With over 25 years of experience and a track record of several lens care products licensed to and sold by partners globally, the team is targeting a novel concept that allows for higher contact lens wear comfort [...]